BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
Rhea-AI Summary
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria, has scheduled its first quarter 2025 financial results conference call and webcast for Thursday, May 15, 2025, at 2:00 p.m. ET. During the call, the company will discuss Q1 2025 financial performance and provide updates on its business operations and programs. Interested participants can join via phone by dialing 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The webcast will be accessible through the Investors section of BiomX's website at www.biomx.com, where it will also be archived for future viewing.
Positive
- None.
Negative
- None.
News Market Reaction – PHGE
On the day this news was published, PHGE declined 3.11%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
BiomX, Inc.
Ben Cohen
Head Corporate Communications
benc@biomx.com
FAQ
When will BiomX (PHGE) report its Q1 2025 earnings?
How can I join BiomX's Q1 2025 earnings call?
What will BiomX discuss in their Q1 2025 earnings call?
Where can I find the replay of BiomX's Q1 2025 earnings webcast?
